Should I discontinue cariprazine (Vraylar) because it is causing suicidal thoughts, increased anxiety, and drowsiness, and switch to aripiprazole (Abilify)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Discontinue Vraylar Immediately Due to Suicidal Thoughts

You must discontinue cariprazine (Vraylar) immediately given the emergence of suicidal thoughts, increased anxiety, and drowsiness. The FDA label explicitly warns about suicidal thoughts and behaviors, particularly during initial treatment and dose changes, and recommends considering discontinuation in patients experiencing emergent suicidal ideation 1.

Critical Safety Concerns with Vraylar

The FDA black box warning for Vraylar specifically addresses suicidal thoughts and behaviors in younger adults. The label states: "Consider changing the therapeutic regimen, including possibly discontinuing VRAYLAR, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors" 1. Your symptoms of self-harm thoughts combined with worsening anxiety represent a clear indication for immediate discontinuation.

Important caveat: Vraylar has a uniquely long half-life due to active metabolite accumulation, meaning adverse effects may persist or even worsen for several weeks after stopping the medication 1. Monitor closely during this washout period.

Concerns About Switching to Aripiprazole (Abilify)

Switching to aripiprazole requires extreme caution and may not be the optimal choice in your situation. Here's why:

Risk of Worsening Symptoms with Aripiprazole

Multiple case reports document that aripiprazole can paradoxically worsen anxiety, agitation, and suicidal ideation, particularly when:

  • Switching from other antipsychotics 2, 3, 4
  • The mechanism involves dopamine receptor upregulation from prior antipsychotic use, where aripiprazole's partial agonist activity may increase dopaminergic activity and worsen anxiety, agitation, and even trigger psychotic decompensation 3, 4
  • One case report describes a patient who died by suicide shortly after switching to aripiprazole 3

Aripiprazole has been specifically associated with increased anxiety, akathisia, and suicidal thoughts when used in mood disorders 2. The research recommends starting with very low doses and close monitoring, with immediate discontinuation if anxiety or suicidal thoughts emerge 2.

Recommended Approach

Immediate Actions:

  1. Stop Vraylar now - do not continue given suicidal ideation
  2. Do NOT immediately start aripiprazole - given your current anxiety and suicidal thoughts, aripiprazole carries significant risk of worsening these symptoms
  3. Ensure safety monitoring for 4-6 weeks as Vraylar clears from your system

Alternative Switching Strategy:

Based on current treatment guidelines 5, 6, if switching from a partial dopamine agonist (like Vraylar) that has failed:

Consider switching to a full D2 antagonist instead, such as:

  • Risperidone
  • Paliperidone
  • Olanzapine (with metformin to prevent weight gain)
  • Amisulpride

These medications have different pharmacodynamic profiles and avoid the partial agonist mechanism that may be contributing to your symptoms 5.

If Aripiprazole Is Still Being Considered:

Only attempt this switch if:

  • You have completely stabilized after stopping Vraylar (4-6 weeks minimum)
  • Suicidal thoughts have fully resolved
  • Anxiety has returned to baseline
  • Start with the lowest possible dose (2 mg or less)
  • Have daily to weekly monitoring for the first month
  • Immediately discontinue if any worsening of anxiety or suicidal thoughts occurs 2

Key Clinical Pitfalls

  • Don't underestimate Vraylar's long washout period - effects persist weeks after stopping
  • Don't assume all atypical antipsychotics are interchangeable - partial agonists (Vraylar, Abilify) have fundamentally different mechanisms than full antagonists
  • Don't rush the switch - allow adequate time for symptom stabilization before introducing new medication
  • Akathisia can masquerade as anxiety - both Vraylar and aripiprazole commonly cause akathisia, which patients often describe as severe anxiety or restlessness

The safest approach is to discontinue Vraylar immediately, allow adequate washout time, and consider a full D2 antagonist rather than another partial agonist like aripiprazole 5, 6, 3, 4.

References

3
Research

Suicidality and psychotic episodes after starting aripiprazole: two case reports.

International clinical psychopharmacology, 2022

Related Questions

A patient currently taking aripiprazole (Abilify) 15 mg daily wishes to switch to cariprazine (Vraylar) 0.5 mg daily; does she need a cross‑taper?
Does Vraylar (cariprazine) help with flashbacks in a patient previously treated with Abilify (aripiprazole) for that indication?
Does aripiprazole (Abilify) worsen suicidal ideation?
Can ropinirole (Requip) be given together with cariprazine (Vraylar) or aripiprazole (Abilify)?
What is the appropriate management plan for a patient presenting with severe suicidal ideation, intention, and psychotic symptoms, including visual hallucinations and command auditory hallucinations, with a history of recent incarceration, homelessness, and possible depressive and manic episodes, currently treated with aripiprazole (Abilify) and hydroxyzine (Vistaril)?
What is the estimated average blood glucose corresponding to a fructosamine level of 364 µmol/L?
In a postmenopausal woman concerned about weight gain, will switching progesterone therapy from oral to vaginal reduce weight gain?
What oral iron regimen should be used to rapidly replenish depleted iron stores?
In a 60-year-old patient with normal sinus rhythm (NSR) on an electrocardiogram (ECG), is an incomplete right bundle‑branch block (RBBB) concerning?
What is the appropriate management for a patient who has swallowed a tablet that became disengaged from its packaging?
Do children with anatomically narrowed nasal passages have disturbed nighttime breathing and sleep?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.